Vitamin D testing in Australia: what the evidence actually says.

Vitamin D is measured in blood as 25-hydroxyvitamin D, written 25(OH)D, which reflects your total body stores. Below 50 nmol/L is deficient; 50–125 nmol/L is the accepted sufficiency range. Roughly one in four Australian adults sits below that line, and more than one in three do in winter. But here is the part almost no wellness article tells you: the three largest randomised trials of vitamin D supplementation ever conducted, together enrolling nearly 50,000 people, found no reduction in cancer, cardiovascular events, fractures or death. Both things are true at once, and understanding why is the difference between using this test well and wasting it.

The key facts, up front

• 23% of Australian adults are deficient (25(OH)D <50 nmol/L). 14% in summer, 36% in winter, per the ABS National Health Measures Survey.
• The big supplementation trials were null. VITAL (n=25,871), D-Health (n=21,315, Australian) and D2d (n=2,423) found no benefit for cancer, cardiovascular disease, mortality or type 2 diabetes.
• Supplementation did not prevent fractures either in generally healthy adults not selected for deficiency or osteoporosis (VITAL fracture analysis, NEJM 2022).
• More is not better. A single annual 500,000 IU dose increased falls by 15% and fractures by 26% in a Melbourne-led randomised trial.
• The Endocrine Society now suggests against routine testing in generally healthy adults without a specific indication. A striking reversal from the same body that popularised widespread screening.
• Deficiency is still real and worth correcting. The null trials tested topping up the already-sufficient. That is a different question from treating genuine deficiency.

What the clinical evidence actually shows

Vitamin D is the most instructive biomarker in The HodieLabs Evidence-Based Clinical Library, not because the evidence is strong, but because it is a case study in how observational associations can dissolve under randomisation.

• VITAL (Manson et al. NEJM 2019): 25,871 US adults randomised to 2,000 IU/day vitamin D3 or placebo. Over a median 5.3 years there was no significant reduction in invasive cancer or major cardiovascular events. Subgroup signals (normal-BMI participants, cancer mortality when the first two years were excluded) were explicitly framed by the investigators as hypothesis-generating, not conclusions.
• D-Health (Neale et al. Lancet Diabetes & Endocrinology 2022): the largest mortality-endpoint vitamin D trial ever run, and it was Australian. 21,315 adults aged 60–84 recruited from the Commonwealth electoral roll, given 60,000 IU monthly for five years. No significant reduction in all-cause mortality, cancer mortality or cardiovascular mortality.
• VITAL fractures (LeBoff et al. NEJM 2022): in the same 25,871 participants, vitamin D3 did not reduce total, non-vertebral or hip fractures in midlife and older adults who were not selected for deficiency, low bone mass or osteoporosis.
• D2d (Pittas et al. NEJM 2019): 2,423 adults with prediabetes given 4,000 IU/day. Progression to type 2 diabetes was not significantly reduced (hazard ratio 0.88). A result compatible with a modest benefit, but not evidence of one. If you want to move that risk, fasting insulin and HbA1c respond to interventions with far better trial support.
• Sanders et al. JAMA 2010, the harm signal: 2,256 older Australian women given a single annual 500,000 IU dose had 15% more falls and 26% more fractures than placebo, with risk concentrated in the three months after each dose. High intermittent bolus dosing is not a convenience shortcut.
• The one positive outlier. VITAL autoimmune disease (Hahn et al. BMJ 2022): vitamin D reduced incident autoimmune disease by 22% (HR 0.78, 95% CI 0.61–0.99). One secondary endpoint, one trial, a confidence interval brushing 1.0. Interesting. Not yet a reason to supplement.

Why the observational studies were so misleading

For two decades, cohort studies consistently linked low 25(OH)D to almost everything. Cancer, heart disease, dementia, infection, early death. The associations were real. The causal interpretation was not.

Low vitamin D is an excellent marker of being unwell, indoors, sedentary, obese or old. Illness reduces sun exposure and outdoor activity; adiposity sequesters vitamin D in fat tissue, lowering serum levels without changing intake; systemic inflammation lowers 25(OH)D directly. In other words, low vitamin D is frequently a consequence of poor health rather than a cause of it, which is exactly the pattern that produces strong observational signals and null randomised trials. This is why we cross-read it against hs-CRP and body composition rather than in isolation.

What the 2024 Endocrine Society guideline changed

In 2024 the Endocrine Society, the body whose 2011 guideline helped drive the global testing boom, published a new prevention guideline that suggests against routine 25(OH)D screening in generally healthy adults, and against routine follow-up testing to guide dosing. Its reasoning is precise: no clinical trial has established outcome-specific 25(OH)D thresholds in healthy populations, so there is no target level that testing could meaningfully steer you toward.

That caveat is recorded directly in the HodieLabs interpretation notes for this biomarker. The 50–125 nmol/L band is the accepted sufficiency range. It is not a validated "optimal for longevity" target, and we do not present it as one.

How HodieLabs interprets your vitamin D result

Every biomarker in the HodieLabs Evidence-Based Clinical Library is interpreted against a named clinical authority standard, never an invented optimal range. For vitamin D (25-OH), measured in nmol/L, we follow the Endocrine Society 2024 standard:

• Below 50 nmol/L, deficient. A genuine clinical state worth correcting, especially where bone, muscle or malabsorption concerns exist.
• 50–125 nmol/L, sufficient. The accepted reference range. Within this band, there is no trial evidence that higher is better.
• 126–150 nmol/L, above optimal. Usually supplement-driven; no demonstrated added benefit.
• Above 150 nmol/L. Monitor. Warrants review for potential toxicity, including checking calcium.

Vitamin D also earns its place as context rather than as a standalone score. A low 25(OH)D alongside a raised alkaline phosphatase, low-normal calcium and declining bone density is a coherent clinical picture that no single one of those markers would reveal alone. That is the argument for panel-based interpretation, not for testing vitamin D in isolation.

The Australian angle: sunshine, seasons and skin

Australia has the world's highest rates of skin cancer and, simultaneously, a real winter vitamin D problem. The 36% winter deficiency figure is not a rounding error. South-eastern Australia sits far enough from the equator that cutaneous synthesis falls sharply between June and August, and the groups most affected are predictable: people with deeply pigmented skin, indoor and shift workers, aged-care residents, those who cover for cultural reasons, and anyone diligently following sun-safety advice.

Medicare's position reflects the evidence rather than the enthusiasm. Since November 2014, MBS item 66833 has restricted rebated 25(OH)D testing to defined clinical indications. Osteoporosis or osteomalacia signs, hyperparathyroidism, abnormal calcium or phosphate, malabsorption, chronic kidney disease, deeply pigmented skin or chronic severe lack of sun exposure, and medications that lower 25(OH)D. Routine screening of healthy adults is deliberately excluded, and testing rates fell after the change before rising again.

The practical takeaway

• Test 25(OH)D, not 1,25-dihydroxy vitamin D. The latter is tightly regulated and can look normal in deficiency.
• If you are deficient, correct it with daily or weekly D3 taken with a fat-containing meal, and retest at around three months. Avoid large annual boluses.
• If you are sufficient, more will not help you live longer on current evidence. Spend the effort on interventions that have trial support. Cardiorespiratory fitness, resistance training, sleep and ApoB control.
• Interpret it in a panel alongside calcium, phosphate, ALP and bone density, not as a standalone wellness number.

The bottom line

Vitamin D is a genuine deficiency state that is common in Australian winters and worth correcting when it is present. It is not a longevity drug. The largest trials ever conducted tested that hypothesis honestly and it did not hold. A preventative health programme that tells you otherwise is selling optimism, not evidence, and the same rigour that produces a negative answer here is what makes a positive answer elsewhere worth acting on.

References

1. Manson JE, Cook NR, Lee IM, et al. Vitamin D supplements and prevention of cancer and cardiovascular disease. N Engl J Med. 2019;380(1):33–44.
2. Neale RE, Baxter C, Romero BD, et al. The D-Health Trial: a randomised controlled trial of the effect of vitamin D on mortality. Lancet Diabetes Endocrinol. 2022;10(2):120–128.
3. LeBoff MS, Chou SH, Ratliff KA, et al. Supplemental vitamin D and incident fractures in midlife and older adults. N Engl J Med. 2022;387(4):299–309.
4. Pittas AG, Dawson-Hughes B, Sheehan P, et al. Vitamin D supplementation and prevention of type 2 diabetes. N Engl J Med. 2019;381(6):520–530.
5. Hahn J, Cook NR, Alexander EK, et al. Vitamin D and marine omega 3 fatty acid supplementation and incident autoimmune disease: VITAL randomized controlled trial. BMJ. 2022;376:e066452.
6. Sanders KM, Stuart AL, Williamson EJ, et al. Annual high-dose oral vitamin D and falls and fractures in older women: a randomized controlled trial. JAMA. 2010;303(18):1815–1822.
7. Demay MB, Pittas AG, Bikle DD, et al. Vitamin D for the prevention of disease: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2024;109(8):1907–1947.
8. Australian Bureau of Statistics. Australian Health Survey: Biomedical Results for Nutrients, 2011–12 (National Health Measures Survey). Canberra: ABS.
9. Australian Government Department of Health. Medicare Benefits Schedule item 66833 (25-hydroxyvitamin D), effective November 2014.

This article is general information, not medical advice. Speak with your GP about what testing and care is appropriate for you.